Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer
The feasibility of longitudinal metastatic biopsies for gene expression profiling in breast cancer is unexplored. Dynamic changes in gene expression can potentially predict efficacy of targeted cancer drugs. Patients enrolled in a phase III trial of metastatic breast cancer with docetaxel monotherap...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-08-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1016/j.molonc.2015.03.011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846150970225983488 |
|---|---|
| author | Theodoros Foukakis John Lövrot Patricia Sandqvist Hanjing Xie Linda S. Lindström Carla Giorgetti Hans Jacobsson Elham Hedayati Jonas Bergh |
| author_facet | Theodoros Foukakis John Lövrot Patricia Sandqvist Hanjing Xie Linda S. Lindström Carla Giorgetti Hans Jacobsson Elham Hedayati Jonas Bergh |
| author_sort | Theodoros Foukakis |
| collection | DOAJ |
| description | The feasibility of longitudinal metastatic biopsies for gene expression profiling in breast cancer is unexplored. Dynamic changes in gene expression can potentially predict efficacy of targeted cancer drugs. Patients enrolled in a phase III trial of metastatic breast cancer with docetaxel monotherapy versus combination of docetaxel + sunitinib were offered to participate in a translational substudy comprising longitudinal fine needle aspiration biopsies and Positron Emission Tomography imaging before (T1) and two weeks after start of treatment (T2). Aspirated tumor material was used for microarray analysis, and treatment‐induced changes (T2 versus T1) in gene expression and standardized uptake values (SUV) were investigated and correlated to clinical outcome measures. Gene expression profiling yielded high‐quality data at both time points in 14/18 patients. Unsupervised clustering revealed specific patterns of changes caused by monotherapy vs. combination therapy (p = 0.021, Fisher's exact test). A therapy‐induced reduction of known proliferation and hypoxia metagene scores was prominent in the combination arm. Changes in a previously reported hypoxia metagene score were strongly correlated to the objective responses seen by conventional radiology assessments after 6 weeks in the combination arm, Spearman's ρ = 1 (p = 0.017) but not in monotherapy, ρ = −0.029 (p = 1). Similarly, the Predictor Analysis of Microarrays 50 (PAM50) proliferation metagene correlated to tumor changes merely in the combination arm at 6 and 12 weeks (ρ = 0.900, p = 0.083 and ρ = 1, p = 0.017 respectively). Reductions in mean SUV were a reliable early predictor of objective response in monotherapy, ρ = 0.833 (p = 0.008), but not in the combination arm ρ = −0.029 (p = 1). Gene expression profiling of longitudinal metastatic aspiration biopsies was feasible, demonstrated biological validity and provided predictive information. |
| format | Article |
| id | doaj-art-89c2141cc3f44e8897ebac1036b4b482 |
| institution | Kabale University |
| issn | 1574-7891 1878-0261 |
| language | English |
| publishDate | 2015-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj-art-89c2141cc3f44e8897ebac1036b4b4822024-11-28T05:26:00ZengWileyMolecular Oncology1574-78911878-02612015-08-01971384139110.1016/j.molonc.2015.03.011Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancerTheodoros Foukakis0John Lövrot1Patricia Sandqvist2Hanjing Xie3Linda S. Lindström4Carla Giorgetti5Hans Jacobsson6Elham Hedayati7Jonas Bergh8Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, SwedenDepartment of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, SwedenDepartment of Radiology and Nuclear Medicine, Karolinska Institutet and University Hospital, Stockholm, SwedenDepartment of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, SwedenDepartment of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, SwedenPfizer Oncology, Milan, ItalyDepartment of Radiology and Nuclear Medicine, Karolinska Institutet and University Hospital, Stockholm, SwedenDepartment of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, SwedenDepartment of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, SwedenThe feasibility of longitudinal metastatic biopsies for gene expression profiling in breast cancer is unexplored. Dynamic changes in gene expression can potentially predict efficacy of targeted cancer drugs. Patients enrolled in a phase III trial of metastatic breast cancer with docetaxel monotherapy versus combination of docetaxel + sunitinib were offered to participate in a translational substudy comprising longitudinal fine needle aspiration biopsies and Positron Emission Tomography imaging before (T1) and two weeks after start of treatment (T2). Aspirated tumor material was used for microarray analysis, and treatment‐induced changes (T2 versus T1) in gene expression and standardized uptake values (SUV) were investigated and correlated to clinical outcome measures. Gene expression profiling yielded high‐quality data at both time points in 14/18 patients. Unsupervised clustering revealed specific patterns of changes caused by monotherapy vs. combination therapy (p = 0.021, Fisher's exact test). A therapy‐induced reduction of known proliferation and hypoxia metagene scores was prominent in the combination arm. Changes in a previously reported hypoxia metagene score were strongly correlated to the objective responses seen by conventional radiology assessments after 6 weeks in the combination arm, Spearman's ρ = 1 (p = 0.017) but not in monotherapy, ρ = −0.029 (p = 1). Similarly, the Predictor Analysis of Microarrays 50 (PAM50) proliferation metagene correlated to tumor changes merely in the combination arm at 6 and 12 weeks (ρ = 0.900, p = 0.083 and ρ = 1, p = 0.017 respectively). Reductions in mean SUV were a reliable early predictor of objective response in monotherapy, ρ = 0.833 (p = 0.008), but not in the combination arm ρ = −0.029 (p = 1). Gene expression profiling of longitudinal metastatic aspiration biopsies was feasible, demonstrated biological validity and provided predictive information.https://doi.org/10.1016/j.molonc.2015.03.011Breast cancerRelapse biopsyPositron emission tomographyHypoxiaSunitinib |
| spellingShingle | Theodoros Foukakis John Lövrot Patricia Sandqvist Hanjing Xie Linda S. Lindström Carla Giorgetti Hans Jacobsson Elham Hedayati Jonas Bergh Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer Molecular Oncology Breast cancer Relapse biopsy Positron emission tomography Hypoxia Sunitinib |
| title | Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer |
| title_full | Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer |
| title_fullStr | Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer |
| title_full_unstemmed | Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer |
| title_short | Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer |
| title_sort | gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer |
| topic | Breast cancer Relapse biopsy Positron emission tomography Hypoxia Sunitinib |
| url | https://doi.org/10.1016/j.molonc.2015.03.011 |
| work_keys_str_mv | AT theodorosfoukakis geneexpressionprofilingofsequentialmetastaticbiopsiesforbiomarkerdiscoveryinbreastcancer AT johnlovrot geneexpressionprofilingofsequentialmetastaticbiopsiesforbiomarkerdiscoveryinbreastcancer AT patriciasandqvist geneexpressionprofilingofsequentialmetastaticbiopsiesforbiomarkerdiscoveryinbreastcancer AT hanjingxie geneexpressionprofilingofsequentialmetastaticbiopsiesforbiomarkerdiscoveryinbreastcancer AT lindaslindstrom geneexpressionprofilingofsequentialmetastaticbiopsiesforbiomarkerdiscoveryinbreastcancer AT carlagiorgetti geneexpressionprofilingofsequentialmetastaticbiopsiesforbiomarkerdiscoveryinbreastcancer AT hansjacobsson geneexpressionprofilingofsequentialmetastaticbiopsiesforbiomarkerdiscoveryinbreastcancer AT elhamhedayati geneexpressionprofilingofsequentialmetastaticbiopsiesforbiomarkerdiscoveryinbreastcancer AT jonasbergh geneexpressionprofilingofsequentialmetastaticbiopsiesforbiomarkerdiscoveryinbreastcancer |